Patent Baristas

In their book iProperty: Protecting Ideas in an Age of Global Innovation, the authors ask that we move past our old views of protecting ideas and look at what is necessary for companies to thrive in the new intense global competition today. They call this new vision the world of iProperty.  The “i” in iProperty […]

Please join the Kentucky BioAlliance for their Annual Meeting and Reception as they explore the Life Cycle of Life Sciences.  Roger Griggs, founder of the Drug Enhancement Company of America, will talk to Kentucky BioAlliance members and guests about his experience in growing five successful life science companies in Kentucky. Following the presentation, the Kentucky […]

For both startups and well-established businesses, intellectual property is a core asset that drives both innovation and brand development. As a result, it is crucial to preemptively protective one’s resources from potential challenges by outside firms whose sole business practice is instigating litigation against operating companies. These “patent trolls” seek to buy up intellectual property […]

If you are a small business and are interested in obtaining early-stage financing to support your cancer research and technology development, you may be in luck. The National Cancer Institute (NCI) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are offering funding opportunities to eligible small businesses and research institutions for […]

“Who do you think was the country’s biggest supplier of prescription drugs in 2007?  Was it Pfizer or Merck or Bristol-Meyers-Squib or Novartis?   No. It was Teva Pharmaceuticals, a generic manufacturer.”    ~ Martin Voet, The Generic Challenge:  Understanding Patents, FDA & Pharmaceutical Life-Cycle Management (Second Edition). The Generic Challenge is about providing the necessary […]

Therapies for Ignored Diseases Last week, the Bill and Melinda Gates Foundation gave Collaborative Drug Discovery (CDD) a $1.9 million grant to help tuberculosis scientists to collaborate to discover new cures for TB, a disease that is resurgent in the 3rd world.   The company provides web-based software that organizes preclinical research data to enable scientists […]

As Congress is considering possible legislation to create an abbreviated pathway for the FDA to approve generic biologic therapies (“biogeneric,” “biosimilar” and “follow-on biologics”), differences in the R&D expense and product cost, and the potential for both new therapies post-approval and second-generation innovations have raised questions about how to achieve the proper balance between innovation […]

In another blow against late claiming, the Court of Appeals for the Federal Circuit denied an appeal from a re-examination because the patent applicants “could have filed the present claims” earlier in the application.  Although I suspect the court was just ticked off because the applicants appeared to be gaming the system – the reexamination […]